You have no items in your shopping cart.
🧬 Trastuzumab Biosimilar Antibody, Research Grade (Anti-HER2 / ERBB2)
Recombinant Anti-HER2 (ERBB2) Biosimilar Monoclonal Antibody for Preclinical Research and Assay Development.
Technical Summary
Biorbyt’s research-grade Trastuzumab biosimilar antibodies are recombinant monoclonal antibodies that mimic trastuzumab-like binding to human HER2 (ERBB2/CD340), a receptor tyrosine kinase involved in cell growth and survival signaling and widely studied in oncology research.
These antibodies are designed for preclinical research applications, enabling consistent evaluation of HER2 target engagement, assay development, and comparative antibody performance in vitro.
- HER2 Binding Specificity – Targets extracellular domain of human HER2 (ERBB2) for receptor-level analysis.
- Validated for ELISA & Flow Cytometry – Suitable for quantitative detection and cell-based profiling.
- Recombinant Biosimilar Format – Optimized for reproducible non-clinical research workflows.
- Multi-Application Use – Supports binding assays, receptor profiling, and biosimilar comparison studies.
1. What Is Trastuzumab Biosimilar Antibody?
Trastuzumab Biosimilar Antibody is a research-grade recombinant monoclonal antibody designed to mimic trastuzumab-like binding to human HER2 (ERBB2 / CD340). HER2 is a receptor tyrosine kinase involved in regulating cell proliferation and survival signaling, and its overexpression is commonly associated with breast and gastric cancer progression.
This antibody is widely used as a reference reagent for HER2-targeted assay development, biosimilar comparison, and antibody functional studies in vitro.
2. Molecular Mechanism of Trastuzumab Biosimilar Antibody (HER2 Target Engagement)
Biorbyt's Trastuzumab Biosimilar Antibody binds specifically to the extracellular domain of human HER2 (ERBB2) on the cell surface, mimicking trastuzumab-like receptor engagement behavior in preclinical research systems.
This binding event interferes with HER2 receptor accessibility and allows controlled evaluation of receptor occupancy and interaction behavior under experimental conditions.
In cellular models, HER2 engagement by the antibody provides a mechanistic basis for studying receptor binding characteristics and comparative antibody performance at the molecular level.
3. Biorbyt Featured Product: Trastuzumab Biosimilar Antibody (orb1173652) Validation Data and Performance Overview
The following experimental validation datasets demonstrate the performance of Biorbyt’s featured trastuzumab biosimilar antibody (orb1173652) across ELISA and flow cytometry platforms.
Overall Performance: orb1173652 exhibits high-affinity and target-specific binding in both biochemical (ELISA) and cellular (FACS) systems, making it suitable as a reference tool for HER2 assay development and biosimilar benchmarking studies.
4. Trastuzumab Biosimilar vs Standard Anti-HER2 Antibody
Feature | Standard Anti-HER2 Antibody | Trastuzumab Biosimilar |
|---|---|---|
Purpose | HER2 detection | Functional HER2 modeling |
Binding profile | Epitope-dependent | Trastuzumab-like |
ELISA suitability | Moderate | Strong validated performance |
Flow cytometry | Basic detection | High-performance binding assay |
Functional studies | Limited | Applicable |
ADC research | Limited relevance | Widely used reference tool |
Biosimilar comparison | Not suitable | Core application |
5. HER2 Antibody Portfolio for Research Applications
Product | SKU | Application | Specification | Price |
|---|---|---|---|---|
Trastuzumab Biosimilar Antibody (HER2 Functional Reference Antibody) | ELISA, FC | 50 μg | $170 | |
Trastuzumab Biosimilar Antibody (Clone 4D5-8) | ELISA, FC, IHC | 0.2 mg | $600 | |
Human Trastuzumab Monoclonal Antibody (Recombinant IgG1, Native Glycosylation) | ELISA, FA, FACS, In vivo | 100 μg | $100 | |
Recombinant HER2 Fab Antibody (High-Affinity HER2 Binding Fragment) | ELISA, FC, WB | 50 μg | $940 | |
Trastuzumab Idiotypic Antibody (Clone BUCC4335) | Blocking, ELISA | 50 μg | $440 |
6. Research Workflows Using Trastuzumab Biosimilar Antibody
- ELISA assay development: Used as a reference reagent for optimizing HER2 binding assays and quantitative detection systems.
- Flow cytometry profiling: Enables identification and comparison of HER2-positive and HER2-negative cell populations.
- Receptor occupancy studies: Applied in evaluating antibody binding levels under different experimental conditions.
- Biosimilar benchmarking: Supports comparative evaluation of candidate HER2-targeting antibodies in preclinical research.
- Antibody engineering research: Used in screening and optimization of HER2-targeted antibody formats.
7. Frequently Asked Questions (Advanced Scientific Version)
Is the Trastuzumab Biosimilar Antibody suitable for HER2 signaling pathway studies?
The Trastuzumab HER2 reference antibody (orb1173652) is designed for HER2 (ERBB2)-targeted binding studies and receptor engagement analysis in preclinical research systems. It can be used to evaluate HER2 receptor interaction and downstream cellular responses in in vitro signaling-related assays, but it is primarily intended as a research tool for receptor-level binding and assay development rather than direct pathway inhibition.
What is the application scope of the Trastuzumab Biosimilar Antibody in HER2 research?
Trastuzumab biosimilar antibodies are widely used in HER2-targeted preclinical research, including ELISA-based binding assays, flow cytometry profiling, and comparative antibody performance evaluation.
Biorbyt’s Trastuzumab biosimilar antibody (orb1173652) is commonly used as a functional reference reagent for HER2 receptor engagement studies and biosimilar benchmarking workflows.
👉 Explore full HER2 antibody portfolio: HER2 Antibody Products
Can the Trastuzumab Biosimilar Antibody be used for evaluating HER2-targeting antibody candidates?
Yes. orb1173652 is widely used as a reference standard for evaluating the binding performance of HER2-targeting antibodies in ELISA and flow cytometry-based assays, supporting comparative biosimilar and antibody engineering studies.
Why is a Trastuzumab biosimilar antibody used instead of clinical trastuzumab in research applications?
Research-grade Trastuzumab biosimilar antibodies such as orb1173652 provide a consistent and cost-effective alternative to clinical-grade trastuzumab for in vitro studies, enabling reproducible HER2 assay development, receptor binding analysis, and antibody performance comparison without clinical constraints.
Does the Trastuzumab Biosimilar Antibody directly inhibit HER2 signaling?
The Trastuzumab HER2 reference antibody (orb1173652) is intended for research use in HER2 binding and receptor interaction studies. It is not designed as a therapeutic inhibitor but can be used to study HER2 engagement and related cellular response patterns in experimental models.
8. References
- Hudis CA. Trastuzumab—Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine. 2007;357(1):39–51. https://www.nejm.org/doi/full/10.1056/NEJMra043186
- Moasser MM. The oncogene HER2: its signaling and transforming functions in human cancer pathogenesis. Oncogene. 2007;26:6469–6487. https://pubmed.ncbi.nlm.nih.gov/17471238/
- Paek KY et al. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar. BioDrugs 33, 661–671 (2019). https://link.springer.com/article/10.1007/s40259-019-00381-2